Abbott has announced the US launch and first commercial uses of the new EnSite Precision cardiac mapping system and Advisor FL Circular Mapping Catheter, Sensor Enabled to map cardiac arrhythmias during ablation treatment.

The first commercial use of the system following US Food and Drug Administration approval occurred at Intermountain Heart Institute at Intermountain Medical Center in Salt Lake City during ablation procedures conducted by electrophysiologist Dr John Day.

Abbott expects its new cardiac mapping technology will quickly become a new standard for use in treating patients experiencing arrhythmias from multiple origins in the heart.

Intermountain Medical Center Heart Institute’s Intermountain Heart Rhythm Specialists medical director Dr Day said: "The new EnSite Precision cardiac mapping system allows better three-dimensional images of the arrhythmias in the heart, which improve the accuracy of what we see during the procedure so we can more precisely treat the patient.

"We were excited to perform the inaugural case in the United States, and we continue to utilise the system daily to provide the best patient care possible."

When catheter ablation is used to treat abnormal heart rhythms, a small area of heart tissue under the tip of the ablation catheter is heated by radio-frequency energy, which creates a lesion or tiny scar. As a result, the tissue is no longer capable of conducting or sustaining the arrhythmia.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

Cardiac mapping offers an inside view of the heart, which enables physicians to visualise and then accordingly navigate cardiac anatomy to deliver more precise ablation therapy.

The new EnSite Precision cardiac mapping system is the latest addition to the company's electrophysiology portfolio.

This next-generation technology is intended to offer automation, flexibility and precision in cardiac mapping during the treatment of patients with abnormal heart rhythms (cardiac arrhythmias).

"The new EnSite Precision cardiac mapping system allows better three-dimensional images of the arrhythmias in the heart."

Its dual-technology platform offers detailed anatomical models and maps to enable more efficient treatment of a wide range of irregular heart rhythms, including complex arrhythmias, such as atrial fibrillation or ventricular tachycardia.

The EnSite Precision cardiac mapping system offers new solutions, such as the EnSite AutoMap Module. This module enables the electrophysiologist to quickly perform morphology matching that identifies the source of the irregular heartbeat.

The EnSite AutoMap Module comes with the new TurboMap feature, which enables physicians to build a map of the heart ten times faster than the present systems using recorded data.

Abbott's electrophysiology business medical director and vice-president of medical affairs Srijoy Mahapatra said: "This next-generation technology was designed in collaboration with some of the world's leading electrophysiologists so that they can quickly and precisely identify the source and substrate source of a patient's irregular heartbeat.

"We expect the EnSite Precision cardiac mapping system to become the new standard for identifying abnormal heart rhythms when tailoring treatment for patients suffering from arrhythmias."

Image: Abbott Ensite Precision Cardiac Mapping. Photo: courtesy of Abbott.